President s legacy. I think that i know from my discussions with foreign leaders of us far that they are hopeful that the United StatesDemocratic Institutions are viewed once again as being strong and endure. And, but i think at the end of the day, you know, its all going to come to fruition. In january 20th. The u. S. Supreme court has begun hearing arguments in a case which could strip 20000000. 00. People of medical insurance justices serve already signaled that theyre unlikely to strike down all of the Affordable Care act. A key piece of president obamas legacy, also known as obamacare. President trump and other republicans want. The law struck down. Russian peacekeeping troops are being deployed in a goanna karabakh following a deal to end 6 weeks of fighting. The disputed region is internationally recognized as part of as the by jan, but is controlled by Ethnic Armenians as aries in the days celebrating whats been seen as a win delivering swathes of territory to their country. But in neighboring armenia, its part of public anger. Mass protests have been taking place across peru after Martin Vickery was removed as president. But just as fought with Police Outside congress in the capital, lima is current remains very popular. Despite the accusations of corruption that led to his impeachment and be a central government, has vowed to continue a military operation in the Northern Tier grey region until a number of conditions are met. They want the regions leaders to face trial, a new administration to be set a band, all their missiles to be destroyed. President Prime Minister ahmed ordered the offensive in degree or most a week ago. Those were the headlines. Ill be back with more news in half an hour here on aljazeera, but next its inside story. Do stay with us. A new hope for a coded 19 vaccine u. S. Firm, pfizer says its candidate has proven 90 percent effective and could be rolled out by the end of the year. But is this realistic and how do we ensure everyone has equal access . This is inside story. Hello and welcome to the program. Im how much i enjoy him. Its being hailed as a great day for science and humanity. U. S. Drug giant pfizer says its covert 1000 vaccine candidate worked on more than 90 percent of people during a mass clinical trial. The company, along with germanys bio on tech, wants to get emergency approval soon, so people can get the vaccination from december. Its raising hopes of an end to a pandemic thats killed more than a 1000000 people and destroyed economies around the world. But scientists are urging caution. Well bring in our guests in a moment 1st, this report from Charley Angela 1300000000 doses by the end of the year. Thats the claim from drug makers, pfizer and biotech. After announcing their vaccine is more than 90 percent effective. Theirs is the 1st successful data from a large scale clinical trial. And widespread vaccinations could roll out by the end of december following an application for an emergency use approval from regulators within weeks. German company, biotech admit theyre still waiting on more results to further prove its safety. Its true that this type of medication has no approval yet, which is why we are carrying out this compatibility study with more than 40000 test persons to find out if there is any intolerance. Even a rare one. What we can prove with this study is that the vaccine is compatible and that side effects are mild to moderate, and that there are no severe side effects. The news of the vaccine sent Global Stock Markets soaring. Scientists welcome the news of the 90 percent effectiveness, much higher than been expected, but also raised questions. We have to know who received it in vaccine, in this 1st trial, and evaluate if this sometimes tick results could be extended also to add the populations which are matched more than in needs for relaxing the they mean all the people people with who are at risk of severe infections and probably were not included in the 1st trial. You know, as the World Health Organizations, Decision Making body met in a largely Virtual Conference questions were already being raised about how any vaccine would be distributed, especially to developing countries. The world has come together as never before to usually slice, same into result of devil or fraud. And im not going to be fairly, as lot with not private people. Why and what reason . Some people left behind 1200000 people have now died of the virus. And more than 50000000, people have quoted 10000000 of them in the u. S. But the pandemic shows no signs of abating with hungry and political, the latest countries in europe to reimpose strict measures. The assembly did have one reason to celebrate the victory of joe biden means the u. S. Will be reestablishing its relationship with the w. H. O. To trump, the many began with truing. The funding the u. S. Brings is key as the organization revealed, well, the worlds expectations of the w. H. O. Have going to magically the budget, hasnt charlie and pfizers is one of a dozen vaccines in the final stages of testing. In august, russia approved the 1st vaccine called sputnik v before large scale safety trials even began. U. S. Biotech firm moderna says its on track to produce 500000000. 00 doses of its an occupation annually from next year. British firm, astra zeneca and Oxford University have resumed testing their candidate, after a participant fell seriously ill in september. And in brazil, the government has halted a trial of trying to sign. Nowak vaccine after what the Health Regulator called a severe adverse event. All right, lets bring in our guests in washington, d. C. , oscar allen, epidemiologist and chief of programs and services for the National Association of county and City Health Officials in the u. S. In new york. And gandhi, who coordinates work at the u. N. Childrens Agency Unicef to roll out a potential covert 1000 vaccine. And in ann arbor michigan out to him vaccine, all a just and Vice President of Vaccine Research and development at blue willow, biology biology. X. , welcome to all of you ali. Let me start with you this data that pfizer released. This was not in a Peer Reviewed medical journal. So this is not yet conclusive evidence that the vaccine is safe and effective. Is it . No, its an interim analysis. And tim and others of gives us such a great outcome. Its really interesting that exceeded all expectations and still we are waiting for the final results which will be idolised after receiving the rest of the data. Of course, this is a great day and a great results, and it does not need to be reviewed because i announce it because what we have there is the, an independent d. S. M. Be looked at the data, the kompany, nothing anybody else. But then independent organization or team, its called the assembly that looks at these things and they seen these great outcomes and they announce it they have to go through the f. D. A. In order to be able to define exactly more details on the, in addition to the excellent data, its also a proof of concept the messenger r. N. A. To can all or she is precious time in men and gives a 90 percent difficulty. Thats a great arm because we have my deodorant, which is also i miss in general on a. So thats a proof of concept and we should expect that one didnt. I would be equally order are close to a c. That to us, shown with the effects seen from beyond tick and pfizer. So that all these things all together gives us a great hope for seeing the light at the end of the tunnel to see that we are going in the right direction. And we will have a vaccine. Of course, there are civil op, any questions that i believe we can talk about that later on. That still need to be answered before we decide. Dont say that we have a vaccine and we are really getting in speak. Oscar, you heard ali was saying there. He said that this was a great outcome thus far. There are still a lot of questions. Of course, this announcement, obviously it reverberated around the world. But there is still a lot that we dont know. So i want to ask you, is it too early to celebrate, and what are exactly the guidelines for rolling out a vaccine . Thank you very much. You know, its very interesting because were still in the throes of identifying what the distribution allocation and even specifically what those plans are. So within the last month or so, the states had a rapid u. S. States. Let me rephrase. I had a rapid timeline where they had to create an disseminate plans for how if they were given an early allocation or any allocation of vaccines, what steps they would take to ensure they get distributed to the communities and to the people that they serve. So specifically with that tell us you have a much varied approach across different geographies and recognizing the logistics thats going to be necessary. In addition to concerns around betsy residency. And in general, target population to ensure that you have enough vaccine, whether its early dissemination or later dissemination provided in that shared approach. Very similar to what we saw in h one n one. So theres going to be a lot of logistics, a lot of apprehension, but also a lot of hope and thats in regard to hopefully we can turn a corner perspective, this particular vaccine and the head of a console. Oscar, you brought up a key word there. Logistics, which is something i was going to ask again about. So let me turn to now because this issue of logistics obviously is of paramount importance. Its going to be very difficult to ensure that a covert 1000 vaccine can be delivered throughout the world. I know unicef has already started laying the ground work on this. Unicef is very experienced as far as trying to set up logistics for the delivery of vaccines around the world. Tell us about your efforts thus far. Certainly. Yeah, and theres a lot of parallels actually to what a skit was saying. So i think for us, you know, were looking to serve the needs globally. And so a lot of the work that weve been doing right now has been to assess the capacity, particular culture in countries around the world, particularly, and middle income countries. Also looking more generally across the programs themselves. All of the issues that will come into play, whether thats advocacy and communications, social mobilization, the programming and training of healthcare workers. And so, so a lot of the work right now is to, is really an assessment that countries are leading themselves, country governments and leaving themselves using a check less than a tool that cho and unicef have developed. And of working through with those countries, stakeholders. And of course, one of the key issues within that is of course im ensuring that there is the cold chain capacity for ages the phrases that will be necessary to roll out. These vaccines will a vaccine that prevents cold with 19 be enough to stop the spread of the virus. Thats a great question because what we know from viral infections is that the injectable vaccines, although it kind of prevent disease in many cases, they would not prevent colonize ation and spread it. Indeed, if they do it, do it for in short period of time and the because we lack what we call in your causally immunity, it would be injectable vaccines. We believe that dick, in this case, the virus can still be around and knows of people even vaccinated, as would be interesting to look at asymptomatic cases in defect. Seen studies that was tell us exactly how long theyve been. 3, how long the virus can stay there and spread it. So basically what we need to really is looking at the colonize ation and thats symptomatic carriers a whole received a vaccine. If thats the case, then we need to start looking at sinking about in new striped issues that can approach a 2nd generation vaccine, which would tackle this problem of color lies ation and to spread. Because in that case, if it didnt make and endemic, you would never get 100 percent immunization and vaccination. And therefore, you would need to find a way to prevent colonize ation. And this sprite, which we call the head of the immunity. And this case that we will be using the final load into a community and therefore we could control it didnt extend and then ix oscar. Id like to talk for a moment about how this particular vaccine is going to work. Because my understanding is usually when one gets vaccinated, youre given either a weekend or a dead part of the virus. But the way that this virus works, its called him, are in a what specifically does that mean . How is this different . So the particular target of this kind of this vaccine, as were speaking might be emirate and r. N. A. It focuses on what is called a spike protein, which on the surface of you isnt very, very, i would say significant general terms. You know, the surface of the, the virus there is a spike protein that allows you to target that level of what we call an immune response. So by utilized in this, this, this target of the spike protein to generate this, you know, logical response. You are not necessarily, we need to create what we call a live attenuated box, where you actually use an, you know, specific live virus through or, or disabled like virus that you say to predict, to prevent that kind of response. So the m. R. In a style of the vaccination is our colleagues mentioned earlier. Its a totally new concept for implementation in the human population. And it provides some great strategies on the flip side. The concern, of course, are the medical countermeasures that are going to be necessary. Most jurisdictions are not going to have ultra cold Storage Facilities for this type of virus or decide to vaccine i should say. And also theres going to be from what we understand the need for to Dose Administration a. So, and in vigils that have to really understand that to get the vaccine, youre not going to be immediately, you know, protected, and you will be quietly fucking those ministrations. So there are a lot of devils in the details, but thats the extent of being tried general and description of the m. R. In a process. Again, if i could ask you to expand a little bit on what you were talking about a few moments ago, because when it comes to the Distribution Logistics here, i mean, you mentioned in your earlier answer, this cold chain thats going to have to exist because it has to be this vaccine is going to have to be kept in cold temperatures. How much more of a challenge does that pose for the distribution of this vaccine . And does this mean that governments are going to have to play a key role in distribution . Yeah, thanks so you know, since working with them is the World Health Organization the Vaccine Alliance and the coalition for epidemic prepared this innovation seppi as part of global Vaccine Access facility known as kovacs. And that facility overall is looking, of course, trying to build a portfolio of vaccines that may be successful, maybe safe, affective and license and ultimately recommended for use throughout the world. And so with that portfolio comes a diversity of needs and in the systems that were looking at Health Systems that were looking at across the low and particular middle income countries. And. And what we want out teams that doing, we have, we have teams of logic stations from the, from the World Health Organization and unicef that are right now. Ready . Doing sess months of the coach aint capacity, particularly in the middle income countries. And looking at building on what weve already been really putting in place over recent years with the support of the b. H. O. And unicef have been putting in place around. 40000 fridge is really that a useful for vaccines that would norm, that kind of reflect the, the normal storage temperatures of most vaccines that we work with. So thats 2. 00 to 8. 00 degree celsius. And those, those facilities, those fridges that are already in place, will, will serve as a, if you like, a, as the foundation of many of the just ticks requirements for many of the products that we see in the pipeline right now. Unicefs assessment of the market that we conducted earlier this year with them. Pits from, from, from many vaccine manufacturers. Gave us a sense that the vast majority of the products in the pipeline, the menu pressures develop as a targeting a 2 to 8 degree celsius requirement. So, so certainly the foundation is in place, it will be, be leveraged as best possible. Of course, there are, there are other vaccines such as they or polio vaccine that require slightly more stringent temperature requirements, which is minus, minus 20 degrees celsius and. And again, because of the almost ubiquitous use of all polio and in the developing world, there is, there is already a degree of capacity for back scenes that might require those kinds of temperatures. And then of course, anything more stringent, theres much more limited use in the developing world. Certainly, the trials of the, some of the abode of vaccines, the conducted predominant in west africa have led to some amount of coaching capacity. Even more stringent temperatures, but certainly is not, not as widespread as if you like the other, the other types of fridges and freezers that i referred to earlier. So i think we need to spend and investment, depending on where vaccines are ultimately recommended for use. And to ensure that the systems you know, have the capacity to absorb alie, i want to take a step back because for those who are unfamiliar with some of the scientific terminology, all of this can be a little bit confusing. So i want to focus on 2 particular things. There is vaccine efficacy, and there is vaccine effectiveness. And these are slightly different terms when it comes to describing how effective a vaccine can be. Could you explain this difference to our viewers and how it applies to the vaccine . Well, facts, significances, the ability of the vaccine to prevent disease in the controlled study and effectiveness. Would you look at the general effectiveness of the vaccine and community and its impact, and therefore, you know, you have to show a ficus, seen it controlled study not look to, to a license to vaccine and for the f. D. A. To evaluate the difficulty of the vaccine. So therefore, you know, these are related to not to be you very much different. So therefore, the ficus e. Is that really what we are looking at in these ongoing Clinical Trials right now. And also a measure of saying that we are really following is the safety as a, as a mentioned in the beginning, its a fierce time in men. And therefore, we would like to look at the safety and in the on going to studies the maximum safety that we are getting is in that median is 2 months. And 2 once by all means is, is a short kind of date. And we would like, we will probably wait for a long term safety later on what by monitoring these people going forward. So there are no shortage when theyre not in a pandemic context. You cannot wait for a year to come to collect all of that. And therefore 5050. 00 double that and the impact of the safety of the vaccine 2 months. Median follow up is, is good enough to give us an indication of what to expect. But there, but still we would like to know more about clint dempsey, oscar, you heard ali there talking about safety. And i want to ask you about the challenges that lie ahead in educating the public into accepting that a vaccine this vaccine, another vaccine that a vaccine is safe. That brings us to the 3rd definition, which is that a Vaccine Hesitancy. And a Vaccine Hesitancy central speaks to the fact that individuals communities excedrin have been hesitant to take in a vaccine for varied amounts of consent. And at this present moment in the United States, one of the concerns is spend bieber tidier. How quickly does vaccine has been developed, you know, has it been processed through a system that really ensures that it is not acacias and effective . And what harm can be put on the population being exposed to a vaccine that they may not feel unspent necessarily gone through that particular parameter. The other piece has been the unfortunate impact we travel over the course of time with respect to backseat deniers and antivaccination or so theres a general antiscience trend which has unfortunately played a role in why not only see the exciting to cern. The fairs but also beaten into this, well theres, theres in the various activity thats being undermined the cause for why that seems to be a push. And then you also have the 3rd component that of those marginalized, communities. And especially speaking here in the u. S. , where we have meetings of color, indigenous populations, brown, black, latino, you name it, who are specifically at a greater risk. And are seen a much harder in touch with this virus and be pandemic. But how, who also had a years and decades of concern around systemic racism and other issues that, that structurally address theyre believed to have based, and the Public Health system or the health care sector. And then the 4th element is that this entire response has actually been laden with what we have seen to be any roshan and a confidence in the Public Health for the scientific community. So when you add all those together, maxine hesitancy gets that big. And it really requires us to have a much significant approach to address and community engagement, education, and ensuring that the information individuals are getting are coming from reliable sources and they can help bolster their competence. Take it back when they become ill. Again, we only have a couple minutes left. Let me ask you if these results that weve heard so far about the vaccine. If they hold up, how would they compared to highly effective childhood vaccines like vaccines for measles . Certainly, i think these, these results are in that ballpark. I wont comment on the, on the efficacy overall, i think, you know, but, but it certainly encouraging overall. And i think it gives confidence more generally that the portfolio of vaccines that kovacs facility and other entities are trying to build is, is, is moving in the right direction. We obviously want am a risk based approach that enables us to, to it, to ensure that the largest number of shots on goal if you like to have, you know, ultimately more than one vaccine available. The kovacs facility itself is looking to get 2000000000. 00 has by the end of next year. And of course, that cant be done. Thats unlikely to be done just by, by one vaccine candidate or one manufacturer. So, so certainly encouraging results. One step along the pathway in the right direction, and i would add, you know, that many of the things that are mentioned for the u. S. , a very relevant of course, in the developing world. And unicef is them, is also very heavily engaged in social listening, trying to understand the sources and that the types of messages that, that were hearing on the ground in low and middle income countries, many of which have ceded by, by anti back seen movements elsewhere in the world, particularly hiring company trees, and trying to design our strategies to roll out any of these, these vaccines as, as, and when they prove insect safe, efficacious, licensed, and obviously recommended for use so that we have the strategies in place both to address hesitancy and of course, the systems in place to absorb the necessary requirements that come with these vaccines, but its a, its a mean karajan, but we still have a way to all right, weve run out of time, so were going to have to leave the conversation there. Thanks so much to all our guests. Oscar alan gandy. And to him and thank you too for watching. You can see the program again any time by visiting our website, aljazeera dot com and further discussion go to our facebook page. Thats facebook dot com, forward slash a. J. Inside story. You can also join the conversation on twitter. We are at a. J. Inside story for me, and the entire team here in doha. I for now as the sun goes down, this shutting down. Russia is a very challenging place to work as a journalist, even though the authorities here say you cant do it, its not allowed to build part of the council. Most always on the look. People are being taken from my new place, the city that we are grabbling a mile away, autumn media go, we go there and we give them a story. Jump into the stream and join our global community. Bio diversity is biosecurity. Is that essential for our species to survive . Be part of the debate . I know you have ideas and you can be part of this conversation when no topic is off the table, the complaints are neutral and all of these cases goal here is to terrorize. And heres the other part of this. Theres no consequence to this stream. On out, is there food for celebration . Food for reconciliation and food from ancient civilizations. Aljazeera wild goes on a mouth watering hole and region me from spain to the middle east. To discover the Hidden History behind some of the regions best loved dishes, savoring the past on out is the whole robin in doha, a reminder of our top stories, the u. S. President elect, joe biden has called Donald Trumps refusal to concede the president ial election. An embarrassment, but biden says nothing will stop the transfer of power in january. Thats despite the Trump Administration reporting lee refusing to assist bidens Transition Team and blocking them from accessing vital resources reports now from washington. D. C. Well, donald trump is keeping a low profile job by putting himself front and center. This was an event to discuss the Affordable Care act. But the president elect questions on other topics and